Another way MET activation occurs in NSCLC is through point mutations, particularly the elimination of exon 14, which is observed in 2−4% of NSCLCs and is more common in lung sarcomatoid carcinomas.73, 218. Here, MET is linked to non-small cell lung carcinoma.